Literature DB >> 16672421

Evaluation of a commercial latex agglutination assay for serological diagnosis of leptospirosis.

C Hull-Jackson1, M B Glass, M D Ari, S L Bragg, S L Branch, C U Whittington, C N Edwards, P N Levett.   

Abstract

Leptospirosis is a febrile zoonosis of worldwide distribution. A latex agglutination assay was evaluated in two studies, the first using a panel of well-characterized sera from patients with leptospirosis and from patients with other disease states and the second, a prospective hospital-based study, evaluating sera from 186 consecutive patients admitted to hospital with acute febrile illness. The confirmed leptospirosis serum panel included paired acute- and convalescent-phase specimens from 40 cases, of which 34 gave positive latex tests (case sensitivity, 85%; 95% confidence interval [95% CI], 70 to 94%). The other diseases represented in the panel of 112 specimens from nonleptospirosis patients included autoimmune diseases, brucellosis, dengue, melioidosis, malaria, syphilis, toxoplasmosis, viral hepatitis, and a number of other viral infections. The specificity of latex agglutination using this panel was 81% (95% CI, 73 to 87%). Among the patients with acute febrile illness, there were 25 cases of leptospirosis and 161 patients with other diagnoses. The sensitivity and specificity of latex agglutination in this group were 88% (95% CI, 72 to 97%) and 98% (95% CI, 95 to 100%), respectively. In this evaluation, the two distinct groups of specimens gave similar results for sensitivity, but specificity was different in each study. The sensitivity and specificity observed for the hospital study were similar to those obtained in evaluations of other rapid tests in the same population. The results of this study suggest that multiple evaluations of new diagnostic assays should be performed, because performance characteristics may vary in different populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16672421      PMCID: PMC1479163          DOI: 10.1128/JCM.44.5.1853-1855.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

Review 1.  Leptospirosis.

Authors:  P N Levett
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

2.  Evaluation of four commercially available rapid serologic tests for diagnosis of leptospirosis.

Authors:  Mary D Bajani; David A Ashford; Sandra L Bragg; Christopher W Woods; Tin Aye; Richard A Spiegel; Brian D Plikaytis; Bradley A Perkins; Maureen Phelan; Paul N Levett; Robbin S Weyant
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

3.  Two methods for rapid serological diagnosis of acute leptospirosis.

Authors:  P N Levett; S L Branch; C U Whittington; C N Edwards; H Paxton
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

4.  Assessment of the efficacy of an IgM-elisa and microscopic agglutination test (MAT) in the diagnosis of acute leptospirosis.

Authors:  P Cumberland; C O Everard; P N Levett
Journal:  Am J Trop Med Hyg       Date:  1999-11       Impact factor: 2.345

5.  Outbreak of leptospirosis among triathlon participants and community residents in Springfield, Illinois, 1998.

Authors:  Juliette Morgan; Shari L Bornstein; Adam M Karpati; Michael Bruce; Carole A Bolin; Constance C Austin; Christopher W Woods; Jairam Lingappa; Carl Langkop; Belinda Davis; Donald R Graham; Mary Proctor; David A Ashford; Mary Bajani; Sandra L Bragg; Kathleen Shutt; Bradley A Perkins; Jordan W Tappero
Journal:  Clin Infect Dis       Date:  2002-05-24       Impact factor: 9.079

6.  Urban epidemic of severe leptospirosis in Brazil. Salvador Leptospirosis Study Group.

Authors:  A I Ko; M Galvão Reis; C M Ribeiro Dourado; W D Johnson; L W Riley
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

7.  Evaluation of two enzyme-linked immunosorbent assay methods for detection of immunoglobulin M antibodies in acute leptospirosis.

Authors:  Paul N Levett; Songee L Branch
Journal:  Am J Trop Med Hyg       Date:  2002-06       Impact factor: 2.345

8.  ELISA for the detection of specific IgM and IgG in human leptospirosis.

Authors:  W J Terpstra; G S Ligthart; G J Schoone
Journal:  J Gen Microbiol       Date:  1985-02

9.  Persistence of anti-leptospiral IgM, IgG and agglutinating antibodies in patients presenting with acute febrile illness in Barbados 1979-1989.

Authors:  P Cumberland; C O Everard; J G Wheeler; P N Levett
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

10.  Detection of specific anti-leptospiral immunoglobulins M and G in human serum by solid-phase enzyme-linked immunosorbent assay.

Authors:  B Adler; A M Murphy; S A Locarnini; S Faine
Journal:  J Clin Microbiol       Date:  1980-05       Impact factor: 5.948

View more
  12 in total

1.  Evaluation of four whole-cell Leptospira-based serological tests for diagnosis of urban leptospirosis.

Authors:  Alan J A McBride; Balbino L Santos; Adriano Queiroz; Andréia C Santos; Rudy A Hartskeerl; Mitermayer G Reis; Albert I Ko
Journal:  Clin Vaccine Immunol       Date:  2007-07-25

2.  Comparative evaluation of recombinant LigB protein and heat-killed antigen-based latex agglutination test with microscopic agglutination test for diagnosis of bovine leptospirosis.

Authors:  Mohandoss Nagalingam; Sushma Rahim Assadi Thirumalesh; Triveni Kalleshamurthy; Nakkala Niharika; Vinayagamurthy Balamurugan; Rajeswari Shome; Pinaki Prasad Sengupta; Bibek Ranjan Shome; Krishnamsetty Prabhudas; Habibur Rahman
Journal:  Trop Anim Health Prod       Date:  2015-06-12       Impact factor: 1.559

Review 3.  Leptospirosis in humans.

Authors:  David A Haake; Paul N Levett
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

4.  Serological analysis by enzyme-linked immunosorbent assay using recombinant antigen LipL32 for the diagnosis of swine leptospirosis.

Authors:  Cláudia P Hartleben; Fernanda M A Leal; Leonardo G Monte; Daiane D Hartwig; Fabiana K Seixas; Sílvio A Vasconcellos; Bibiana Brihuega; Odir A Dellagostin
Journal:  Curr Microbiol       Date:  2012-10-14       Impact factor: 2.188

5.  Recombinant multiepitope protein for diagnosis of leptospirosis.

Authors:  Xu'ai Lin; Yin Chen; Jie Yan
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

6.  Evaluation of leptospiral recombinant antigens MPL17 and MPL21 for serological diagnosis of leptospirosis by enzyme-linked immunosorbent assays.

Authors:  Tatiane R Oliveira; Mariana T Longhi; Zenaide M de Morais; Eliete C Romero; Roberta M Blanco; Karin Kirchgatter; Silvio A Vasconcellos; Ana L T O Nascimento
Journal:  Clin Vaccine Immunol       Date:  2008-09-17

7.  Features of two new proteins with OmpA-like domains identified in the genome sequences of Leptospira interrogans.

Authors:  Aline F Teixeira; Zenaide M de Morais; Karin Kirchgatter; Eliete C Romero; Silvio A Vasconcellos; Ana Lucia T O Nascimento
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

8.  Accuracy of a dual path platform (DPP) assay for the rapid point-of-care diagnosis of human leptospirosis.

Authors:  Scott A Nabity; Guilherme S Ribeiro; Carolina Lessa Aquino; Daniele Takahashi; Alcinéia Oliveira Damião; André H O Gonçalves; Demócrito B Miranda-Filho; Rena Greenwald; Javan Esfandiari; Konstantin P Lyashchenko; Mitermayer G Reis; Marco A Medeiros; Albert I Ko
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01

9.  Lipopolysaccharide Specific Immunochromatography Based Lateral Flow Assay for Serogroup Specific Diagnosis of Leptospirosis in India.

Authors:  Shanmugam Vanithamani; Santhanam Shanmughapriya; Ramasamy Narayanan; Veerapandian Raja; Murugesan Kanagavel; Karikalacholan Sivasankari; Kalimuthusamy Natarajaseenivasan
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

10.  Diagnostic efficacy of lsa63 antigen for human leptospirosis.

Authors:  Safar Ali Alizadeh; Seyyed Saeed Eshraghi; Mohammad Reza Pourmand; Taghi Naserpour; Gholamreza Abdollahpour; Abbas Rahimiforoshani; Reza Najafipour
Journal:  Iran Red Crescent Med J       Date:  2014-03-05       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.